PRQR · ProQR Therapeutics N.V.

ProQR Therapeutics is advancing its Axiomer RNA editing platform through a strategic partnership with Ginkgo Bioworks, which provides access to the Nebula autonomous lab comprising over 50 instruments. This collaboration addresses a key bottleneck in AI-enabled drug discovery by boosting experimental data generation throughput and speed, enabling ProQR's AI models to better predict drug candidates and shorten discovery timelines. Ginkgo's strategic equity investment underscores the partnership's mutual value, signaling external validation of ProQR's AI approach. Complementing this, ProQR has formed an AI Advisory Board with prominent experts including Eric Durand (Owkin), David Ruau (NVIDIA), Thomas Wolf (Hugging Face), and others, to guide AI application in optimizing Axiomer editing oligonucleotides. CEO Daniel A. de Boer highlighted the AI model's development over 18 months, which significantly accelerates and improves editing oligonucleotides. Investors should note the near-term milestone of ProQR's first AI-generated development candidates advancing to clinical trial application in mid-2026, with initial data by year-end, positioning Axiomer for rapid pipeline expansion. The virtual investor event today will provide further pipeline details, new programs with clinical readouts, and AX-0810's primary indication, offering transparency into execution plans.